[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2216021T3 - Farmaceutisk sammensætning til behandling af overaktiv blære - Google Patents

Farmaceutisk sammensætning til behandling af overaktiv blære

Info

Publication number
DK2216021T3
DK2216021T3 DK08843784.3T DK08843784T DK2216021T3 DK 2216021 T3 DK2216021 T3 DK 2216021T3 DK 08843784 T DK08843784 T DK 08843784T DK 2216021 T3 DK2216021 T3 DK 2216021T3
Authority
DK
Denmark
Prior art keywords
overactive
blower
treatment
pharmaceutical composition
pharmaceutical
Prior art date
Application number
DK08843784.3T
Other languages
English (en)
Inventor
Masanori Suzuki
Masashi Ukai
Akiyoshi Ohtake
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2216021(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DK2216021T3 publication Critical patent/DK2216021T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK08843784.3T 2007-11-02 2008-10-30 Farmaceutisk sammensætning til behandling af overaktiv blære DK2216021T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007285802 2007-11-02
PCT/JP2008/069736 WO2009057685A1 (ja) 2007-11-02 2008-10-30 過活動膀胱治療用医薬組成物

Publications (1)

Publication Number Publication Date
DK2216021T3 true DK2216021T3 (da) 2012-11-05

Family

ID=40591069

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08843784.3T DK2216021T3 (da) 2007-11-02 2008-10-30 Farmaceutisk sammensætning til behandling af overaktiv blære

Country Status (12)

Country Link
US (2) US20100240697A1 (da)
EP (1) EP2216021B1 (da)
JP (1) JP5263170B2 (da)
CA (1) CA2704298C (da)
CY (1) CY1113670T1 (da)
DK (1) DK2216021T3 (da)
ES (1) ES2393525T3 (da)
HR (1) HRP20121078T1 (da)
PL (1) PL2216021T3 (da)
PT (1) PT2216021E (da)
SI (1) SI2216021T1 (da)
WO (1) WO2009057685A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013002511A2 (pt) * 2010-08-03 2017-06-27 Altherx Inc combinações de agonistas de receptores adrenérgicos beta - 3 e antagonistas receptores muscarínicos para tratamento da bexica hiperativa
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
SG11201501415RA (en) * 2012-08-31 2015-05-28 Astellas Pharma Inc Orally administered medical composition
PL3192512T3 (pl) * 2014-09-09 2020-03-31 Astellas Pharma Inc. Nowa kompozycja farmaceutyczna do zapobiegania i/albo leczenia nietrzymania moczu
AU2015358378A1 (en) 2014-12-03 2017-06-29 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
WO2017186593A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Tablets comprising mirabegron and solifenacin
WO2017186598A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Modified release tablet composition comprising mirabegron
CN117695286A (zh) 2017-06-06 2024-03-15 住友制药(苏州)有限公司 使用维贝隆以治疗膀胱过度活动症
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2022006336A1 (en) * 2020-07-01 2022-01-06 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
EP4159199A1 (en) 2021-09-29 2023-04-05 Lotus Pharmaceutical Co., Ltd. Combined formulation of mirabegron and solifenacin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
AU9462198A (en) 1997-10-17 1999-05-10 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
CN100355419C (zh) * 2002-06-07 2007-12-19 安斯泰来制药有限公司 治疗膀胱过度活动的药物
KR100967070B1 (ko) 2002-11-07 2010-07-01 아스텔라스세이야쿠 가부시키가이샤 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
ES2290741T3 (es) * 2003-04-04 2008-02-16 Dynogen Pharmaceuticals Inc. Metodo de tratamiento de trastornos del tracto urinario inferior.
KR20060124603A (ko) * 2003-11-03 2006-12-05 베링거 인겔하임 인터내셔날 게엠베하 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물
WO2005087231A1 (ja) 2004-03-16 2005-09-22 Astellas Pharma Inc. ソリフェナシン含有組成物
WO2006090759A1 (ja) * 2005-02-25 2006-08-31 Astellas Pharma Inc. ソリフェナシン含有医薬
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity

Also Published As

Publication number Publication date
EP2216021A4 (en) 2010-11-03
US8772315B2 (en) 2014-07-08
JP5263170B2 (ja) 2013-08-14
CA2704298A1 (en) 2009-05-07
CY1113670T1 (el) 2016-06-22
SI2216021T1 (sl) 2013-01-31
EP2216021A1 (en) 2010-08-11
PT2216021E (pt) 2012-11-06
US20100240697A1 (en) 2010-09-23
US20130150402A1 (en) 2013-06-13
JPWO2009057685A1 (ja) 2011-03-10
CA2704298C (en) 2015-07-21
WO2009057685A1 (ja) 2009-05-07
EP2216021B1 (en) 2012-10-17
HRP20121078T1 (hr) 2013-01-31
ES2393525T3 (es) 2012-12-26
PL2216021T3 (pl) 2013-03-29

Similar Documents

Publication Publication Date Title
DK2216021T3 (da) Farmaceutisk sammensætning til behandling af overaktiv blære
LTPA2018014I1 (lt) Farmacinė kompozicija 514
LTC2140867I2 (lt) Farmacinė kompozicija
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI0721651A2 (pt) Composição farmacêutica
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK3354276T3 (da) Sammensætninger til behandlingen af gastrointestinal inflammation
DK2303330T4 (da) Farmaceutiske sammensætninger til behandling af parkinsons sygdom
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
BRPI0715712A2 (pt) Composição farmacêutica
DK2114386T3 (da) Farmaceutisk sammensætning til behandling af diabeteskomplikationer
BRPI0719393A2 (pt) Composição farmacêutica
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0716445A2 (pt) composiÇço farmacÊutica
DK2285413T3 (da) Farmaceutisk sammensætning
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0921313A2 (pt) composição farmaucêutica